SELINEXOR COMBINED WITH POMALIDOMIDE AND LOW DOSE DEXAMETHASONE (SPD) IN A RELAPSED / REFRACTORY MULTIPLE MYELOMA PATIENT POPULATION
Author(s): ,
Christine Chen
Affiliations:
Princess Margaret Cancer Center,Toronto,Canada
,
Heather Sutherland
Affiliations:
Vancouver General Hospital,Vancouver,Canada
,
Rami Kotb
Affiliations:
Cancer Care Manitoba,Manitoba,Canada
,
Michael Sebag
Affiliations:
Royal Victoria Hospital,Montreal,Canada
,
Darrell White
Affiliations:
Dalhousie University and QEII Health Sciences Center,Halifax,Canada
,
William Bensinger
Affiliations:
Swedish Cancer Center,Seattle,United States
,
Cristina Gasparetto
Affiliations:
Duke University Cancer Center,Durham,United States
,
Richard LeBlanc
Affiliations:
Hôpital Maisonneuve-Rosemont,Montreal,Canada
,
Chris Venner
Affiliations:
Cross Cancer Institute,Edmonton,Canada
,
Suzanne Lentzsch
Affiliations:
Columbia University,New York,United States
,
Gary Schiller
Affiliations:
UCLA Ronald Reagan Medical Center,Los Angeles,United States
,
Brea Lipe
Affiliations:
University of Rochester Medical College,New York,United States
,
Aldo Del Col
Affiliations:
Myeloma Canada,Laval,Canada
,
Michael Kauffman
Affiliations:
Karyopharm Therapeutics,Newton,United States
,
Sharon Shacham
Affiliations:
Karyopharm Therapeutics,Newton,United States
,
Jacqueline Jeha
Affiliations:
Karyopharm Therapeutics,Newton,United States
,
Jean-Richard Saint-Martin
Affiliations:
Karyopharm Therapeutics,Newton,United States
,
Jatin Shah
Affiliations:
Karyopharm Therapeutics,Newton,United States
Nizar Bahlis
Affiliations:
Southern Alberta Cancer Research Institute,Calgary,Canada
EHA Learning Center. Chen C. Jun 15, 2018; 215036
Christine Chen
Christine Chen

Access to EHA Members only content is an EHA membership benefit. Click here to join EHA or renew your membership here.


Abstract
Discussion Forum (0)
Rate & Comment (0)

Abstract: PF586

Type: Poster Presentation

Presentation during EHA23: On Friday, June 15, 2018 from 17:30 - 19:00

Location: Poster area

Background
The nuclear export protein exportin 1 (XPO1) is overexpressed in a wide variety of cancers including multiple myeloma (MM). Selinexor is a first-in-class Selective Inhibitor of Nuclear Export (SINE) compound that binds and inactivates XPO1. Selinexor forces nuclear retention and reactivation of cell cycle regulators such as p53, IkB, and Rb. Pomalidomide/dexamethasone (Pd) is approved in relapsed/refractory MM (RRMM) with an overall response rate (ORR) of 30% and progression-free survival (PFS) rate of 3.6 months in patients (pts) having received a prior proteasome inhibitor (PI) and IMiD.  Strategies to improve the ORR and PFS are needed.  In murine MM models, the combination of selinexor with IMiDs shows synergistic anti-MM activity and good tolerability.

Aims
This Ph 1b/2 (NCT02343042), dose escalation study was designed to determine the maximum tolerated dose (MTD) and recommended phase 2 dose (RP2D) for the safety, tolerability and efficacy of the combination of selinexor, pomalidomide, and low dose dex (SPd) in pts with RRMM.

Methods
Pts with RRMM who received ≥ 2 prior therapies including lenalidomide (len) and a PI were enrolled. Selinexor was evaluated in 2 different dosing schedules of once-weekly (QW, 60; 80 mg) or twice-weekly (BIW, 60; 80 mg), with pomalidomide (pom) 4 mg PO daily, and dexamethasone (dex) 20 mg BIW or 40 mg QW.

Results
As of Feb 27th 2018, 33 pts (16 male / 17 female) have been enrolled.The median age is 61 years, with a median of 4 (range, 2 – 9) prior treatment regimens. Thirty-one patients were IMiD refractory (20 len, 11 pom/len). Six dose limiting DLTs were observed: G3 fatigue (60 mg BIW, pom 4 mg), G3 febrile neutropenia (FN) (60 mg BIW, pom 3 mg), G3 FN and G4 neutropenia (ANC) (80 mg QW, pom 4), G3 thrombocytopenia (PLT) (80 mg QW, pom 3 mg) and 4 missed doses in Cycle 1 due to symptomatic hyponatremia (80 mg BIW, pom 4 mg). Enrollment on selinexor 80 mg QW, pom 3 mg is ongoing. Common treatment related Grade 1/2 adverse events (AEs) include: nausea (48%), fatigue (42%), anorexia (45%) and diarrhea (30%). Grade 3/4 AEs include: ANC (55%), PLT (30%), and anemia (27%). Twenty-seven pts were evaluable for response. Responses rates can be seen in Table 1. Median PFS is 11.6 months with a median follow up of 7.7 months. 

Table 1. SPd – Response Rates in Evaluable Patients 

Prior Therapy Status

 

N*

 

ORR

CBR

Pom Naïve & Len Refractory or Relapsed

19

12 (63%)

14 (74%)

Pom & Len Refractory

8

3 (38%)

5 (63%)

Overall Response Rate= VGPR + PR, Clinical Benefit Rate= VGPR + PR + MR (*Includes 1 unconfirmed PR and 1 unconfirmed MR)

Conclusion
Conclusions – Enrollment is ongoing to evaluating once weekly selinexor in combination with Pd. This all oral combination of selinexor, pom and dex (SPd) has significant clinical activity with an ORR 63% in pom naive pts with heavily pretreated MM compared to previously published data of 30% ORR. No unexpected adverse events were noted. Phase 1 dose escalation of the combination of SPd is ongoing to define the RP2D. SPd appears active and supports further clinical development in RRMM.

Session topic: 14. Myeloma and other monoclonal gammopathies - Clinical

Keyword(s): Dexamethasone, Imids, Multiple Myeloma

Code of conduct/disclaimer available in General Terms & Conditions
Anonymous User Privacy Preferences

Strictly Necessary Cookies (Always Active)

MULTILEARNING platforms and tools hereinafter referred as “MLG SOFTWARE” are provided to you as pure educational platforms/services requiring cookies to operate. In the case of the MLG SOFTWARE, cookies are essential for the Platform to function properly for the provision of education. If these cookies are disabled, a large subset of the functionality provided by the Platform will either be unavailable or cease to work as expected. The MLG SOFTWARE do not capture non-essential activities such as menu items and listings you click on or pages viewed.


Performance Cookies

Performance cookies are used to analyse how visitors use a website in order to provide a better user experience.



Google Analytics is used for user behavior tracking/reporting. Google Analytics works in parallel and independently from MLG’s features. Google Analytics relies on cookies and these cookies can be used by Google to track users across different platforms/services.


Save Settings